Eosinophilia: A Comprehensive Review For Pharmacy Practice

  • Paspula Soumya Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India
  • Bujagouni Swapna Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India
  • Atiya Nasreen Tara Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India
  • T. Mangilal Department of Pharmaceutics, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India
  • Saniya Naaz Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India
  • Shazaa Department of Pharmacy Practice, Smt. Sarojini Ramulamma College of Pharmacy, Palamuru University, Seshadri Nagar, Mahabubnagar District, Telangana, India

Abstract

Eosinophilia is defined as an elevated eosinophil count in the peripheral blood and is often associated with a wide range of clinical conditions. This review discusses the aetiology, classification, and pathophysiological mechanisms of eosinophilia, with special attention to diseases such as eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic esophagitis (EoE), and paediatric eosinophilia. Diagnostic approaches, treatment strategies, and implications for pharmacy practice are also explored. A comprehensive understanding of eosinophilia is vital for accurate diagnosis, targeted therapy, and effective patient counselling.

Keywords: Eosinophilia, EGPA, Eosinophilic Esophagitis, Paediatrics, Pharmacy Practice

References

1. Gigon, L., Fettrelet, T., Yousefi, S., Simon, D., & Simon, H. U. (2023). Eosinophils from A to Z. Allergy, 78(7), 1810–1846. https://doi.org/10.1111/all.15751
2. Palacionyte, J., Januskevicius, A., Vasyle, E., Rimkunas, A., Bajoriuniene, I., Miliauskas, S., &Malakauskas, K. (2022). IL-5 and GM-CSF, but not IL-3, promote the proliferative properties of inflammatory-like and lung resident-like eosinophils in the blood of asthma patients. Cells, 11(23), 3804. https://doi.org/10.3390/cells11233804
3. Roufosse, F., & Weller, P. F. (2010). Practical approach to the patient with hypereosinophilia. Journal of Allergy and Clinical Immunology, 126(1), 39–44. https://doi.org/10.1016/j.jaci.2010.04.009
4. Simon, D., & Simon, H. U. (2007). Eosinophilic disorders. Journal of Allergy and Clinical Immunology, 119(6), 1291–1300. https://doi.org/10.1016/j.jaci.2007.03.037
5. Gotlib, J. (2017). World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology, 92(11), 1243–1259. https://doi.org/10.1002/ajh.24880
6. Comarmond, C., &Cacoub, P. (2014). Eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Seminars in Respiratory and Critical Care Medicine, 35(4), 471–481. https://doi.org/10.1055/s-0038-1669454
7. Caminati, M., Menzella, F., Guidolin, L., & Senna, G. (2019). Targeting eosinophils: Severe asthma and beyond. Drugs in Context, 8, 212587. https://doi.org/10.7573/dic.212587
8. Dellon, E. S., & Hirano, I. (2020). Dupilumab in adults and adolescents with eosinophilic esophagitis. New England Journal of Medicine, 383, 2317–2328. https://doi.org/10.1056/NEJMoa2006481
9. Hirano, I., et al. (2020). Cendakimab in eosinophilic esophagitis. Gastroenterology, 159(6), 2049–2062.e8. https://doi.org/10.1053/j.gastro.2020.07.027
10. Valent, P., et al. (2012). Consensus on eosinophilic disorders. Journal of Allergy and Clinical Immunology, 130(3), 607–612. https://doi.org/10.1016/j.jaci.2012.06.021
11. Shomali, W., & Gotlib, J. (2022). World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 97(11), 1294–1317. https://doi.org/10.1002/ajh.26868
12. Valet, P., et al. (2012). Reactive eosinophilia causes. Journal of Allergy and Clinical Immunology, 130(3), 607–612. https://doi.org/10.1016/j.jaci.2012.06.021
13. Shomali, W., & Gotlib, J. (2022). Molecular stratification in hypereosinophilic syndrome. American Journal of Hematology, 97(11), 1294–1317. https://doi.org/10.1002/ajh.26868
14. Dellon, E. S., & Hirano, I. (2018). Organ-restricted eosinophilic diseases. Gastroenterology, 154(2), 319–332. https://doi.org/10.1053/j.gastro.2017.10.014
15. Simon, D., Rothenberg, M. E., et al. (2010). Refining the definition of hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology, 126(1), 45–49. https://doi.org/10.1016/j.jaci.2010.03.027
16. Crane, M. M., et al. (2010). Incidence of myeloproliferative hypereosinophilic syndrome in the United States. Journal of Allergy and Clinical Immunology, 126(1), 179–181. https://doi.org/10.1016/j.jaci.2010.03.019
17. Rothenberg, M. E., & Hogan, S. P. (2006). Eosinophil biology. Annual Review of Immunology, 24, 147–174. https://doi.org/10.1146/annurev.immunol.24.021605.090722
18. Gleich, G. J. (2000). Mechanisms of eosinophil-associated inflammation. Journal of Allergy and Clinical Immunology, 105(4), 651–663. https://doi.org/10.1067/mai.2000.107634
19. Roufosse, F., Cogan, E., & Goldman, M. (2004). Diagnosis and management of hypereosinophilic syndromes. Allergy, 59(7), 673–689. https://doi.org/10.1111/j.1398-9995.2004.00577.x
20. Ogbogu, P. U., Rosing, D. R., & Horne, M. K. (2007). Cardiovascular manifestations of hypereosinophilic syndromes. Immunology and Allergy Clinics of North America, 27(3), 457–475. https://doi.org/10.1016/j.iac.2007.04.003
21. Rothenberg, M. E., et al. (2008). Mepolizumab for hypereosinophilic syndrome. New England Journal of Medicine, 358, 1215–1228. https://doi.org/10.1056/NEJMoa070615
22. Kuang, F. L., et al. (2019). Benralizumab for PDGFRA-negative hypereosinophilic syndrome. New England Journal of Medicine, 381, 1241–1253. https://doi.org/10.1056/NEJMoa1902221
23. Hirano, I., et al. (2022). Dupilumab efficacy in eosinophilic esophagitis. Gastroenterology, 162(6), 1776–1786. https://doi.org/10.1053/j.gastro.2022.01.030
24. Kuang, F. L., et al. (2020). Reslizumab pilot study for hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology: In Practice, 8(1), 165–173. https://doi.org/10.1016/j.jaip.2019.07.039
25. Kuang, F. L., et al. (2022). Real-world biologic therapy in hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology, 149(2), 458–471. https://doi.org/10.1016/j.jaci.2021.06.027
26. Comarmond, C., et al. (2013). Clinical characteristics and long-term follow-up of the 383 patients in the French vasculitis study group cohort of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Arthritis & Rheumatism, 65(1), 270–281. https://doi.org/10.1002/art.37771
27. Wechsler, M. E., et al. (2017). Mepolizumab in refractory eosinophilic granulomatosis with polyangiitis. New England Journal of Medicine, 376, 1921–1932. https://doi.org/10.1056/NEJMoa1700509
28. Jayne, D. R. W., et al. (2021). Avacopan in ANCA-associated vasculitis. New England Journal of Medicine, 384, 599–609. https://doi.org/10.1056/NEJMoa2006483
29. Dellon, E. S., & Hirano, I. (2018). Epidemiology of eosinophilic esophagitis. Gastroenterology, 154(2), 319–332. https://doi.org/10.1053/j.gastro.2017.10.014
30. Rothenberg, M. E. (2004). Pathogenesis of eosinophilic gastrointestinal disorders. Journal of Allergy and Clinical Immunology, 113(1), 11–28. https://doi.org/10.1016/j.jaci.2003.09.031
31. Hirano, I., et al. (2022). Dupilumab in eosinophilic esophagitis: Phase 3 trial results. Gastroenterology, 162(6), 1776–1786. https://doi.org/10.1053/j.gastro.2022.01.030
32. Licari, A., et al. (2020). Biologics in eosinophilic esophagitis: A systematic review and meta-analysis. Expert Review of Clinical Immunology, 16(11), 1105–1115. https://doi.org/10.1080/1744666X.2020.183
33. Runge, T. M., et al. (2023). Artificial intelligence–assisted histology in eosinophilic esophagitis. Clinical Gastroenterology and Hepatology, 21(5), 1037–1046. https://doi.org/10.1016/j.cgh.2022.08.025
34. Chiu, A., et al. (2021). Pediatric eosinophilia outcomes: A multicenter study. Journal of Allergy and Clinical Immunology: In Practice, 9(8), 2778–2789. https://doi.org/10.1016/j.jaip.2021.03.060
35. Butt, N. M., et al. (2017). Geography-based review of eosinophilia: Etiology, prevalence, and implications. British Journal of Haematology, 176(4), 553–572. https://doi.org/10.1111/bjh.14460
36. Cacoub, P., et al. (2011). DRESS syndrome: A review of current knowledge and treatment. American Journal of Medicine, 124(6), 588–597. https://doi.org/10.1016/j.amjmed.2011.01.017
37. Kaufman, L. D., et al. (1991). Eosinophilia–myalgia syndrome: Clinical features and outcomes. Annals of Internal Medicine, 114(6), 426–434. https://doi.org/10.7326/0003-4819-114-6-426
38. Wechsler, M. E., et al. (2021). Biologic therapy duration in hypereosinophilic syndrome: Long-term outcomes. New England Journal of Medicine, 385, 830–840. https://doi.org/10.1056/NEJMoa2035218
39. Chehade, M., et al. (2020). Non-eosinophilic esophagitis eosinophilic gastrointestinal disorders: Characterization and outcomes. Journal of Allergy and Clinical Immunology: In Practice, 8(2), 626–635. https://doi.org/10.1016/j.jaip.2019.09.045
Statistics
5 Views | 1 Downloads
How to Cite
Paspula, S., Bujagouni, S., Tara, A. N., T, M., Naaz, S., & Shazaa, S. (2026). Eosinophilia: A Comprehensive Review For Pharmacy Practice. Journal of Integral Sciences, 9(1), 16-20. Retrieved from https://jisciences.com/index.php/journal/article/view/137
Issue
Volume 9, Issue 1, 2026
Section
Review Article(s)

Copyright © Author(s) retain the copyright of this article.